Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Thrombolysis in high-risk patients with acute pulmonary embolism: underuse of a life-saving treatment in the real-world setting.

Galié N, Manes A, Dardi F, Palazzini M.

Eur Heart J. 2019 May 27. pii: ehz296. doi: 10.1093/eurheartj/ehz296. [Epub ahead of print] No abstract available.

PMID:
31132085
2.

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF.

Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

PMID:
30982349
3.

An insider view on the World Symposium on Pulmonary Hypertension.

Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Lancet Respir Med. 2019 Jun;7(6):484-485. doi: 10.1016/S2213-2600(19)30111-0. Epub 2019 Apr 4. No abstract available.

PMID:
30956061
4.

Role and management of extracorporeal life support after surgery of chronic thromboembolic pulmonary hypertension.

Martin-Suarez S, Gliozzi G, Fiorentino M, Loforte A, Ghigi V, Di Camillo M, Galiè N, Pacini D.

Ann Cardiothorac Surg. 2019 Jan;8(1):84-92. doi: 10.21037/acs.2019.01.02.

5.

Left Main Coronary Artery Extrinsic Compression in Patients With Pulmonary Arterial Hypertension: Technical Insights and Long-Term Clinical Outcomes After Stenting.

Saia F, Dall'Ara G, Marzocchi A, Dardi F, Palazzini M, Manes A, Taglieri N, Marrozzini C, Rinaldi A, Galiè N.

JACC Cardiovasc Interv. 2019 Feb 11;12(3):319-321. doi: 10.1016/j.jcin.2018.08.002. No abstract available.

PMID:
30732740
6.

A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension.

Barozzi C, Galletti M, Tomasi L, De Fanti S, Palazzini M, Manes A, Sazzini M, Galiè N.

Sci Rep. 2019 Jan 24;9(1):753. doi: 10.1038/s41598-018-37277-0.

7.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

8.

Evaluation of Macitentan in Patients With Eisenmenger Syndrome.

Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J, Papadakis K, Pulido T, Galiè N; MAESTRO Study Investigators.

Circulation. 2019 Jan 2;139(1):51-63. doi: 10.1161/CIRCULATIONAHA.118.033575.

9.

Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.

Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Danays T, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Klok FA, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G, Konstantinides SV.

Clin Res Cardiol. 2019 Jul;108(7):772-778. doi: 10.1007/s00392-018-1405-1. Epub 2018 Dec 18.

10.

An overview of the 6th World Symposium on Pulmonary Hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir J. 2019 Jan 24;53(1). pii: 1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. No abstract available.

11.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

12.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

13.

Extracorporeal cardiopulmonary support in acute high-risk pulmonary embolism: still waiting for solid evidence.

Galiè N, Palazzini M, Manes A.

Eur Heart J. 2018 Dec 14;39(47):4205-4207. doi: 10.1093/eurheartj/ehy507. No abstract available.

PMID:
30239710
14.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

15.

Pulmonary Arterial Hypertension: Combination Therapy in Practice.

Burks M, Stickel S, Galiè N.

Am J Cardiovasc Drugs. 2018 Aug;18(4):249-257. doi: 10.1007/s40256-018-0272-5. Review.

16.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

17.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

18.

Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease.

Galiè N, Manes A, Dardi F, Palazzini M.

Eur Heart J. 2018 Apr 14;39(15):1265-1268. doi: 10.1093/eurheartj/ehx751. No abstract available.

PMID:
29293952
19.

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.

Klok FA, Ageno W, Barco S, Binder H, Brenner B, Duerschmied D, Empen K, Faggiano P, Ficker JH, Galiè N, Ghuysen A, Held M, Heydenreich N, Huisman MV, Jiménez D, Kozak M, Lang IM, Lankeit M, Münzel T, Petris A, Pruszczyk P, Quitzau K, Schellong S, Schmidt KH, Stefanovic BS, Verschuren F, Wolf-Puetz A, Meyer G, Konstantinides SV; PEITHO-2 Investigators.

Thromb Haemost. 2017 Dec;117(12):2425-2434. doi: 10.1160/TH17-06-0434. Epub 2017 Dec 6.

PMID:
29212130
20.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
21.

Reply: Left Main Extrinsic Compression in Pulmonary Arterial Hypertension: From Identification to Percutaneous Coronary Intervention Optimization.

Saia F, Palazzini M, Taglieri N, Manes A, Dardi F, Rinaldi A, Gotti E, Galiè N.

J Am Coll Cardiol. 2017 Nov 7;70(19):2460-2461. doi: 10.1016/j.jacc.2017.08.067. No abstract available.

22.

Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply.

Palazzini M, Dardi F, Galiè N.

Eur J Heart Fail. 2018 May;20(5):943. doi: 10.1002/ejhf.969. Epub 2017 Oct 11. No abstract available.

23.

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.

Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM.

Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug.

24.

Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina.

Galiè N, Saia F, Palazzini M, Manes A, Russo V, Bacchi Reggiani ML, Dall'Ara G, Monti E, Dardi F, Albini A, Rinaldi A, Gotti E, Taglieri N, Marrozzini C, Lovato L, Zompatori M, Marzocchi A.

J Am Coll Cardiol. 2017 Jun 13;69(23):2808-2817. doi: 10.1016/j.jacc.2017.03.597.

25.

Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.

Palazzini M, Dardi F, Manes A, Bacchi Reggiani ML, Gotti E, Rinaldi A, Albini A, Monti E, Galiè N.

Eur J Heart Fail. 2018 Feb;20(2):248-255. doi: 10.1002/ejhf.860. Epub 2017 May 2.

26.

Use of β-Blockers in Pulmonary Hypertension.

Perros F, de Man FS, Bogaard HJ, Antigny F, Simonneau G, Bonnet S, Provencher S, Galiè N, Humbert M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003703. doi: 10.1161/CIRCHEARTFAILURE.116.003703. Review.

PMID:
28364092
27.

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G.

J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039.

28.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

29.

A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension.

Leone MB, Giannotta M, Palazzini M, Cefarelli M, Martìn Suàrez S, Gotti E, Bacchi Reggiani ML, Zompatori M, Galiè N.

Radiol Med. 2017 Jul;122(7):495-504. doi: 10.1007/s11547-017-0750-x. Epub 2017 Mar 18.

PMID:
28316030
30.

Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.

Galiè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, Varanese L, Esler A, Harmon C, Palazzini M.

Int J Cardiol. 2017 May 15;235:67-72. doi: 10.1016/j.ijcard.2017.02.094. Epub 2017 Feb 22.

PMID:
28279499
31.

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24.

32.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

33.

Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension.

Rasciti E, Sverzellati N, Silva M, Casadei A, Attinà D, Palazzini M, Galiè N, Zompatori M.

Radiol Med. 2017 Apr;122(4):257-264. doi: 10.1007/s11547-016-0714-6. Epub 2016 Dec 26.

PMID:
28025781
34.

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research.

Hoeper MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, Bonderman D, Olsson KM, Gibbs JSR, Dorfmuller P, Guazzi M, Galiè N, Manes A, Handoko ML, Vonk-Noordegraaf A, Lankeit M, Konstantinides S, Wachter R, Opitz C, Rosenkranz S.

Eur Heart J. 2017 Oct 7;38(38):2869-2873. doi: 10.1093/eurheartj/ehw597. No abstract available.

PMID:
28011705
35.

Future perspectives in pulmonary arterial hypertension.

Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N.

Eur Respir Rev. 2016 Dec;25(142):381-389. doi: 10.1183/16000617.0084-2016. Review.

36.

Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.

Maron BA, Galiè N.

JAMA Cardiol. 2016 Dec 1;1(9):1056-1065. doi: 10.1001/jamacardio.2016.4471.

37.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Erratum in: Chest. 2018 May;153(5):1287.

38.

Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].

Berger RMF, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M.

Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. Epub 2016 Aug 24. No abstract available.

PMID:
27623401
39.

The difficult diagnosis of pulmonary vascular disease in heart failure.

Galiè N, Manes A, Palazzini M.

Eur Respir J. 2016 Aug;48(2):311-4. doi: 10.1183/13993003.00854-2016. No abstract available.

40.

Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.

Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N.

J Heart Lung Transplant. 2017 Apr;36(4):399-406. doi: 10.1016/j.healun.2016.04.013. Epub 2016 May 6.

PMID:
27282418
41.
42.

Treatment of pulmonary hypertension.

Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N.

Lancet Respir Med. 2016 Apr;4(4):323-36. doi: 10.1016/S2213-2600(15)00542-1. Epub 2016 Mar 12. Review.

PMID:
26975811
43.

2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M.

Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. doi: 10.1016/j.rec.2016.01.002. No abstract available.

PMID:
26837729
44.

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.

Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW.

Lancet Respir Med. 2016 Feb;4(2):129-37. doi: 10.1016/S2213-2600(15)00544-5. Epub 2016 Jan 19.

46.

[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M.

Kardiol Pol. 2015;73(12):1127-206. doi: 10.5603/KP.2015.0242. Polish. No abstract available.

47.

Management of pulmonary hypertension.

Essop MR, Galie N, Badesch DB, Lalloo U, Mahomed AG, Naidoo DP, Ntsekhe M, Williams PG.

S Afr Med J. 2015 Jun;105(6):437-9.

PMID:
26716153
48.

What's new in the European Society of Cardiology/European Respiratory Society Pulmonary Hypertension Guidelines?

Humbert M, Galie N.

Eur Heart J. 2016 Jan 1;37(1):4-5. doi: 10.1093/eurheartj/ehv636. No abstract available.

PMID:
26712889
49.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

50.

GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension.

Galiè N, Manes A, Palazzini M.

Breathe (Sheff). 2015 Sep;11(3):233-6. doi: 10.1183/20734735.111115.

Supplemental Content

Support Center